- ImmunoGen (IMGN) forms a partnership with CytomXs Therapeutics to develop Probody-drug conjugate therapies for the treatment of cancer.
- The co-operation brings together ImmunoGen's ADC technology for targeting cancer cells with CytomXs's Probody antibodies, which are designed to remain inert in healthy tissue but be activated in diseased cells. (PR)
ImmunoGen forges co-operation agreement with CytomXs
Jan 9 2014, 08:45 ET